American Glaucoma Society

AGS Map About AGS Become a Member Locate a Member Near YouLinks to Resources AGS Abstracts Contact AGS AGS Home  

Scientific Poster Sessions:

    Friday, March 7, 2003 7:00 am – 7:45 am (Poster 1-20)

  1. Development of Evidence-Based Treatment Recommendations for the Medical Management of Glaucoma. Initial Findings: Definitions of Disease States and Goals of Therapy

  2. Anne L.Coleman

  3. A Comparison Of Latanoprost, Bimatoprost, And Travoprost In Patients With Elevated Intraocular Pressure: A 12-Week, Masked-Evaluator, Multicenter Study

  4. Richard Parrish

  5. Comparison of IOP-Lowering Efficacy of Bimatoprost

  6. Monte Dirks

  7. Stability of Latanoprost in a Community Setting

  8. Rohit Varma

  9. Patient Persistency With Topical Prostaglandin Therapy In The Management Of Glaucoma

  10. Gail F. Schwartz

  11. A Diurnal Evaluation of IOP in Patients Treated With Travatan® or Xalatan®

  12. Harvey DuBiner

  13. Efficacy of Bimatoprost 0.03% in Glaucoma or Ocular Hypertension Patients Non- Responsive to Latanoprost 0.005%

  14. Robert Williams

  15. Clinical and Economic Outcomes Of Latanoprost, Bimatoprost, Or Travoprost Therapy In Glaucoma Patients: A Three-month Retrospective Study

  16. Gail F. Schwartz

  17. Comparing Bimatoprost To Timolol In Patients With Glaucoma Or Ocular Hypertension: Results After Two Years

  18. John Cohen

  19. Ocular Hypotensive Efficacy of Bimatoprost 0.03% and Travoprost 0.004% in Patients with Glaucoma or Ocular Hypertension

  20. Louis Cantor

  21. Efficacy and Safety of Changing to Latanoprost 0.005% From Other Monotherapy Treatment

  22. Thom Zimmerman

  23. Frequency of Adjunctive Medication Use Associated with Travoprost, Bimatoprost and Latanoprost Therapy

  24. Alan Robin and Trong Le

  25. Hyperemia And Myalgia: A 28 Day Prospective Double-Masked Comparison Of Travoprost And Bimatoprost Therapy in Primary Open Angle Glaucoma And Ocular Hypertension

  26. Alan Robin

  27. An Evaluation of IOP Changes in Patients Switched From Brimonidine Monotherapy to Travoprost® Monotherapy in the S.T.A.R.T. Trial

  28. Martin Kaback

  29. An Analysis of Patients Switched From Latanoprost and One Adjunctive Medication Therapy to Travatan® Monotherapy in the S.T.A.R.T. Trial

  30. Paul Schacknow

  31. Optimization of Plastic Materials for Travatan® Containers

  32. Howard Barnebey

  33. An Evaluation of the Comfort of Alphagan® P Compared with Alphagan® in Irritated Eyes

  34. Thomas K. Mundorf

  35. Comparison of Inflammatory Cell Infiltration in the Conjunctiva of Patients Using Chronic Topical Glaucoma Medications

  36. Robert Noecker

  37. Comparison of Alphagan vs Alphagan P on Rabbit Corneal Epithelium
  38. Robert Noecker

  39. A double-masked, randomized, parallel study of the safety and efficacy of Timolol LA in patients with ocular hypertension or open-angle glaucoma

  40. Thomas K. Mundorf

    Saturday, March 8, 2003 7:00 am – 7:45 am (Poster 21-40)

  41. Primary Open Angle Glaucoma With Heterogenous Onset is Linked to Chromosome 2 in a Peruvian Family

  42. Rodolfo A. Perez-Grossmann

  43. The Rate of Disease Progression is Accelerated by the TIGR/MYOC Mt.1 Variant in POAG Patients: Independent Analyses of Effects on Optic Disc and Visual Field Measures of Damage

  44. George L. Spaeth

  45. A Model To Help Evaluate The Cost Of Glaucoma Screening

  46. Kevin D. Frick

  47. Does Community Visual Field Screening Encourage Participants to Have Eye Exams?

  48. Steven L. Mansberger

  49. A Novel Way of Estimating the Course of Glaucoma

  50. George L. Spaeth

  51. Optic Nerve Evaluation – Pilot Study with Specialists and General Ophthalmologists

  52. Paul Lee

  53. The Effect of Pupillary Dilation on Retinal Nerve Fiber Layer Thickness Measurements Using Optical Coherence Tomography (OCT-3)
  54. Samiah Zafar

  55. A Cross-sectional Analysis Of The Blue Arc Entoptic Phenomenon In A Clinic- based Population

  56. Louis Pasquale

  57. Evaluation of the Accuracy of the Proview Intraocular Pressure Monitor Compared to Applanation Tonometry

  58. Ramesh Ayyala

  59. Comparison of Pre-operative and Post-operative IOP measurements in Lasik Patients using the Proview Eye Pressure Monitor and a Goldmann Applanation Tonometer

  60. Anjali Hawkins

  61. Retro-Iridial Lines of Vogt and Pigment Dispersion

  62. Sayoko E. Moroi

  63. Selective Laser Trabeculoplasty Significantly Decreases Intraocular Pressure and Reduces Medication Use

  64. Sean Thomas

  65. Short-Term Intraocular Pressure Results of a Modified Viscocanalostomy

  66. Bruce Cameron

  67. Short-Term Intraocular Pressure Results of a Modified Viscocanalostomy Combined with Cataract Extraction

  68. Bruce Cameron

  69. Histopathologic Correlation of Viscocanalostomy Dissection

  70. Thomas W Samuelson

  71. The Hypertensive Phase after Glaucoma Drainage Implant Surgery

  72. Kouros Nouri-Mahdavi

  73. Optic Nerve Changes Following Posterior Insertion of Glaucoma Drainage Device in a Rabbit Model

  74. Ramesh Ayyala

  75. Risk Of Aqueous Misdirection In Phacoemulsification Post-Acute Angle Closure Glaucoma

  76. Christoph Kranemann

  77. Plateau Iris & Phacoemulsification – Surprising UBM Findings

  78. Christoph Kranemann

  79. Ophthalmologist and pharmaceutical personnel knowledge of new PhRMA marketing code

  80. Jonathan Myers

::: top of page ::: home :::